Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | BUB1 | O43683 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23744430 | 1.00 | CTSL (0.45) | CTSLCTSBCTSKBUB1TSHR | |
| SCHEMBL16398139 | 0.85 | TSHR (0.57) | CTSLCTSBCTSKTSHRCYP2C19 | |
| SCHEMBL16398138 | 0.85 | TSHR (0.57) | CTSLCTSBCTSKTSHRCYP2C19 | |
| SCHEMBL17019782 | 0.83 | TSHR (0.58) | CTSLCTSBCTSKTSHRTAAR1 | |
| SCHEMBL1928095 | 0.83 | TSHR (0.58) | CTSLCTSBCTSKTSHRTAAR1 | |
| SCHEMBL23728530 | 0.83 | CTSL (0.41) | CTSLCTSBCTSKBUB1TSHR | |
| SCHEMBL3398972 | 0.81 | ALDH1A1 (0.55) | CTSLCTSBCTSKTSHRSMN1; SMN2 | |
| SCHEMBL22849511 | 0.81 | ALDH1A1 (0.55) | CTSLCTSBCTSKTSHRSMN1; SMN2 | |
| SCHEMBL23744979 | 0.79 | CTSL (0.50) | CTSLCTSBCTSKTSHRTAAR1 | |
| SCHEMBL2374859 | 0.79 | CTSL (0.50) | CTSLCTSBCTSKTSHRTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230122219-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| EP-4100004-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021158634-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230122219-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CTSL 941/4885CTSB 527/4885CTSK 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.